Correlation Between Serum Magnesium & Zinc with Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) In Patients with Metabolic Syndrome

Abstract

Listen

Translate article

Metabolic syndrome (MS) increases cardiovascular disease and death risk. Many studies have found a link between vascular inflammation and metabolic disorders. Discovering unique and specific blood-based indicators for vascular inflammation, particularly in metabolic syndrome related to obesity, such as (lipoprotein-associated phospholipase A2) and Lp-PLA2, could provide valuable assistance in identifying individuals at an elevated risk for cardiovascular incidents. Lp-PLA2 has been implicated in metabolic dysregulation, playing a crucial role in the onset of microvascular dysfunction and the exacerbation of oxidative stress. Lp-PLA2 is essential in the pathogenesis of atherosclerosis and may be used as a biomarker to predict future cardiovascular events. The study comprised 200 participants categorized into two groups: individuals diagnosed with MS (Metabolic Syndrome) (Test, n = 100) and those without MS (controls, n = 100). The serum activity levels of hs-CRP and Lp-PLA2 were measured and subsequently analysed for correlation with micronutrients (magnesium (Mg) and zinc (Zn)) and lipoprotein markers (Ox LDL, Apo-A1, and Apo-B). The study showed a significant correlation between Lp-PLA2 and the Mg level of patients with MS, whereas Hs-CRP did not exhibit a significant correlation. The test population did not exhibit a noteworthy elevation in oxidized LDL level, despite the presence of inflammatory changes as indicated by the level of Lp-PLA2. A significant correlation was observed between the Zn level in patients with MS and Lp-PLA2, whereas Ox LDL did not exhibit a significant correlation. The current study revealed a significant link between Mg and Zn and CVD risk in the Kerala population. The study found elevated levels of LpPLA2, an emerging biomarker for cardiovascular risk, in people with MS